In the first wave of COVID-19, up to 20% of patients had skin lesions with variable characteristics. There is no clear evidence of the involvement of the SARS-CoV-2 virus in all cases; some of these lesions may be secondary to drug hypersensitivity. To analyze the possible cause of the skin lesions, we performed a complete allergology study on 11 patients. One year after recovery from COVID-19, we performed a lymphocyte transformation test (LTT) and Th1/Th2 cytokine secretion assays for PBMCs. We included five nonallergic patients treated with the same drugs without lesions. Except for one patient who had an immediate reaction to azithromycin, all patients had a positive LTT result for at least one of the drugs tested (azithromycin, clavulanic acid, hydroxychloroquine, lopinavir, and ritonavir). None of the nonallergic patients had a positive LTT result. We found mixed Th1/Th2 cytokine secretion (IL-4, IL-5, IL-13, and IFN-γ) in patients with skin lesions corresponding to mixed drug hypersensitivity type IVa and IVb. In all cases, we identified a candidate drug as the culprit for skin lesions during SARS-CoV-2 infection, although only three patients had a positive drug challenge. Therefore, it would be reasonable to recommend avoiding the drug in question in all cases.
Background: Symmetrical drug‐related intertriginous and flexural exanthema (SDRIFE) is a rare hypersensitivity reaction characterized by symmetric erythematous rashes in intertriginous regions, triggered by systemic drugs. Although self‐limiting, SDRIFE can significantly impact quality of life, requiring accurate diagnosis and management. Objectives: This study aimed to describe the clinical characteristics, diagnostic approaches, and implicated pharmacological agents in the largest reported SDRIFE series, providing insights to improve diagnosis and treatment. Materials and Methods: A retrospective observational study was conducted between 2018 and 2024. Data on demographics, clinical features, implicated drugs, and diagnostic tests—including drug provocation tests (DPTs), lymphocyte transformation tests (LTTs), and intradermal tests—were analyzed. Results: Among 41 patients, the mean age was 66.6 years, with frequent polypharmacy complicating diagnosis. Beta‐lactam antibiotics and iodinated contrast agents were the most implicated drugs. Nine previously unreported drugs were identified as triggers. DPT confirmed causality in six cases, and LTT aided in three complex cases. Avoidance of the suspected drug or pharmacological group was the main therapeutic measure. Conclusions: Systematic medication reviews and standardized protocols are crucial for SDRIFE diagnosis. DPT remains the gold standard, while LTT adds value in complex cases, avoiding unnecessary drug restrictions and expanding therapeutic options.
In the first wave of COVID-19, up to 20% of patients had skin lesions with variable characteristics. There is no clear evidence of the involvement of the SARS-CoV-2 virus in all the cases; some of these lesions may be secondary to drug hypersensitivity. To analyze the possible cause of the skin lesions, we performed a complete allergology study on 11 patients. One year after recovery from COVID-19, we performed a lymphocyte transformation test (LTT) and Th1/Th2 cytokine secretion assays of PBMC. We included 5 nonallergic patients treated with the same drugs without lesions. Except for one patient who had an immediate reaction to azithromycin, all patients had a positive LTT to at least one of the drugs tested (azithromycin, clavulanic acid, hydroxychloroquine, lopinavir, and ritonavir). None of the nonallergic patients had a positive LTT. We found mixed Th1/Th2 cytokine secretion (IL-4, IL-5, IL-13, and IFN-γ) in patients with skin lesions corresponding to mixed drug hypersensitivity type IVa and IVb. In all cases, we identified a candidate drug as the culprit for skin lesions during SARS-CoV-2 infection, although only three patients had a positive drug challenge. Therefore, it would be reasonable to recommend avoiding the drug in question in all cases.